Liveyon’s Live ‘Pure-Cast Podcast Explores Hair Regeneration Success With Stem-Cell Injections

Top Los Angeles’ Dermatologist Dr. Ben Behnam Joins Show To Discuss His ‘Tremendous Success’ Restoring Hair With Stem Cell Treatment


Combating misconceptions surrounding the field of regenerative medicine and the use of stem cells, industry leader Liveyon, LLC’s latest video podcast took a deep dive into the subject of hair restoration.

Los Angeles’ top dermatologist, Dr. Ben Behnam, joined Liveyon CEO John Kosolcharoen and Director of Education Dr. Alan Gaveck on the latest episode of Liveyon Pure-Cast for an in-depth conversation on common misconceptions, scientific breakthroughs and popular issues surrounding hair regeneration.

Although still an experimental industry, Dr. Behnam has seen unprecedented success treating hair loss with stem cell injections. Departing from traditional treatments such as oral medication and PRP injections—both of which have low success rates— Dr. Behnam said stem cell injections “cause a huge growth of hair within four months.”

“I always say when my patients come in, PRP does not work—and if you read the clinical studies, PRP works at best on 65 percent of patients,” Dr. Behnam said. “When we transferred from PRP to stem cells, a majority of the patients actually saw a huge improvement with just one session.”

Both PRP and stem cell treatment involve injecting growth factors into the scalp to stimulate hair growth. However, while growth factors injected into with PRP treatments get washed away quickly, Dr. Behnam explained that stem cell injected growth factors continuously release into the scalp as if a patient was receiving nonstop injections.

This innovative approach to hair restoration stimulates and regenerates thinning hair, reversing hair miniaturization.

“From the beginning, I’ve always used Liveyon stem cells, and honestly I don’t trust any other company,” Dr. Behnam said.

A pioneer in the stem cell industry and manufacturer of the highly acclaimed Liveyon Pure© regenerative therapy umbilical cord stem cell product line, Liveyon sets itself apart within the highly competitive industry with its strong commitment to safety, education, and innovation.

Liveyon launched ‘Liveyon Pure Cast,’ to bring to light the truth about this emerging field and connecting doctors, researchers, patients, and the general public directly with well-respected industry leaders. The podcast provides a complimentary resource for clients of the company’s new product line.

Founded in 2016, Liveyon is pushing the boundaries of regenerative medicine with its innovative take on product research and development, manufacturing and distribution, and commitment to safety and transparency. Liveyon and Liveyon Labs Inc. are committed to achieving unparalleled stem cell potency through high live nucleated cell counts, while following validation protocols that produce an extremely consistent product for the most efficacious outcomes. The company’s dynamic ability to adapt to changing market trends and execute on opportunities has fortified its exponential growth and the company is poised to continue making a huge impact in the industry 2019.

“We welcome you to share this journey with us,” Dr. Gaveck said. “The future of this dynamic new industry is here and the results Liveyon and other industry leaders in the regenerative medicine field are already achieving are going to change our world for the better. Each week, we are creating compelling educational and uniquely entertaining live stream broadcasts and delivering ‘in the now’ insight into cellular science and a regenerative medicine lifestyle.”

To stay up-to-date on the regenerative medicine industry and receive notices of free upcoming live streaming video events, please subscribe to ‘Liveyon Pure-Cast.’


For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

Want to learn more about Liveyon Stem Cells? Contact us for more information.

Translate »


Medical Professional Viewing Only (Disclaimer)

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.